Biocon Biologics set to reap biosimilar insulin glargine opportunity in US

Drugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit growth in the next several quarters, primarily from the US market.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news